Literature DB >> 12791772

Tyrosine phosphorylation of the beta3-subunit of the alphaVbeta3 integrin is required for embrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor I receptor.

Yan Ling1, Laura A Maile, David R Clemmons.   

Abstract

Ligand occupancy of the alphaVbeta3 integrin is required for IGF-I receptor (IGF-IR) phosphorylation of an appropriate duration and for stimulation of IGF-I actions. In vascular smooth muscle cells (SMCs), the tyrosine phosphatase SHP-2 regulates the duration of IGF-IR phosphorylation and biological actions. We determined the role of ligand occupancy of the alphaVbeta3 integrin on beta3 phosphorylation and studied the role of beta3 phosphorylation in regulating both SHP-2 recruitment to the cell membrane and IGF-I-dependent biological responses. Vitronectin binding to alphaVbeta3 induced tyrosine phosphorylation of the beta3-subunit in subconfluent SMCs and was accompanied by increased association of SHP-2 with beta3. In confluent SMCs, the beta3-subunit was constitutively phosphorylated leading to basal binding of SHP-2. The Src kinase inhibitor PP2 caused a concentration-dependent decrease in beta3 phosphorylation and resulted in decreased SHP-2 association with beta3 and with the cell membrane. In contrast to control cells, SMCs expressing a mutant beta3 that had two tyrosines changed to phenylalanines showed a 89.9 +/- 1.2% decrease in beta3 phosphorylation. This decrease was associated with reduced SHP-2 binding to nonphosphorylated beta3 and a corresponding decrease in the membrane association of SHP-2. When IGF-I was added to cells expressing mutant beta3, SHP-2 was not recruited to the Src homology 2 domain-containing tyrosine phosphatase substrate-1 or to IGF-IR. This was associated with prolonged IGF-IR phosphorylation and an impaired cellular DNA synthesis response to IGF-I. These results define a mechanism by which ligand occupancy of alphaVbeta3 regulates the SMC response to IGF-I.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12791772     DOI: 10.1210/me.2003-0143

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  25 in total

1.  A monoclonal antibody against alphaVbeta3 integrin inhibits development of atherosclerotic lesions in diabetic pigs.

Authors:  Laura A Maile; Walker H Busby; Timothy C Nichols; Dwight A Bellinger; Elizabeth P Merricks; Michael Rowland; Umadevi Veluvolu; David R Clemmons
Journal:  Sci Transl Med       Date:  2010-02-10       Impact factor: 17.956

Review 2.  The role of Src homology 2 containing protein tyrosine phosphatase 2 in vascular smooth muscle cell migration and proliferation.

Authors:  Machender R Kandadi; Matthew S Stratton; Jun Ren
Journal:  Acta Pharmacol Sin       Date:  2010-09-27       Impact factor: 6.150

Review 3.  Role of the integrin alphaVbeta3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress.

Authors:  David R Clemmons; Laura A Maile; Yan Ling; J Yarber; Walker H Busby
Journal:  Growth Horm IGF Res       Date:  2007-04-06       Impact factor: 2.372

4.  Integrin alphavbeta3 is a coreceptor for human cytomegalovirus.

Authors:  Xin Wang; David Y Huang; Shu-Mei Huong; Eng-Shang Huang
Journal:  Nat Med       Date:  2005-04-17       Impact factor: 53.440

5.  Identification of novel SHPS-1-associated proteins and their roles in regulation of insulin-like growth factor-dependent responses in vascular smooth muscle cells.

Authors:  Xinchun Shen; Gang Xi; Yashwanth Radhakrishnan; David R Clemmons
Journal:  Mol Cell Proteomics       Date:  2009-03-18       Impact factor: 5.911

6.  Insulin-like growth factor (IGF) signaling requires αvβ3-IGF1-IGF type 1 receptor (IGF1R) ternary complex formation in anchorage independence, and the complex formation does not require IGF1R and Src activation.

Authors:  Masaaki Fujita; Yoko K Takada; Yoshikazu Takada
Journal:  J Biol Chem       Date:  2012-12-14       Impact factor: 5.157

7.  A novel fibroblast growth factor-1 (FGF1) mutant that acts as an FGF antagonist.

Authors:  Satoshi Yamaji; Jun Saegusa; Katsuaki Ieguchi; Masaaki Fujita; Seiji Mori; Yoko K Takada; Yoshikazu Takada
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

8.  Glucose regulation of thrombospondin and its role in the modulation of smooth muscle cell proliferation.

Authors:  Laura A Maile; Lee B Allen; Christopher F Hanzaker; Katherine A Gollahon; Paul Dunbar; David R Clemmons
Journal:  Exp Diabetes Res       Date:  2010-06-20

9.  Glucose regulation of integrin-associated protein cleavage controls the response of vascular smooth muscle cells to insulin-like growth factor-I.

Authors:  Laura A Maile; Byron E Capps; Emily C Miller; Lee B Allen; Umadevi Veluvolu; Ariel W Aday; David R Clemmons
Journal:  Mol Endocrinol       Date:  2008-02-21

10.  p66shc negatively regulates insulin-like growth factor I signal transduction via inhibition of p52shc binding to Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 leading to impaired growth factor receptor-bound protein-2 membrane recruitment.

Authors:  Gang Xi; Xinchun Shen; David R Clemmons
Journal:  Mol Endocrinol       Date:  2008-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.